ID-119031166 is under clinical development by ILEAD Biomedical Science and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase I drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ID-119031166 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ID-119031166 overview

ID-11903 is under development for the treatment of nonalcoholic steatohepatitis (NASH). It acts by targeting farnesoid X receptor (FXR). The therapeutic drug candidate is a new chemical synthetic drug. It is administered through oral route.

ILEAD Biomedical Science overview

iLEAD Biomedical Science, a subsidiary of Ildong Pharmaceutical Co Ltd, engaged in research and development of novel drugs with focus in the area of small molecule medicinal chemistry for the treatment of various diseases. The company is headquartered in Hwaseong-si, Gyeonggi-do, South Korea.

For a complete picture of ID-119031166’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.